Affinity Asset Advisors, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 13, 2025), Affinity Asset Advisors, LLC reported 68 stock positions worth $588.3 million. Its top holding was Xenon Pharmaceuticals (XENE) at 7.7% of the portfolio, followed by Apogee Therapeutics (APGE, 7.2%) and Arcellx (ACLX, 5.5%). Compared with Q3 2024, it opened 14 new positions, sold out of 16, added to 21 and reduced 20. The biggest buy was Verona Pharma (VRNA, shares +2%) and the biggest sale an exit from Kura Oncology (KURA).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001773195
- Portfolio Value
- $588.3M (Q4 2024)
- SEC Filing
- 0001839882-25-008942 ↗ filed Feb 13, 2025
Holdings Value
Holdings 68 stocks · $588.3M
| XENE Xenon Pharmaceuticals Inc. | 7.74% | 1,161,237 | $45.5M | Add +1.5% |
| APGE Apogee Therapeutics Inc. | 7.17% | 931,728 | $42.2M | Add +40.3% |
| ACLX Arcellx Inc. | 5.54% | 425,000 | $32.6M | Add +6.3% |
| ALKS Alkermes PLC | 5.38% | 1,100,000 | $31.6M | Add +10.0% |
| TEVA Teva Pharmaceutical-SP ADR | 5.24% | 1,400,000 | $30.9M | No change |
| VRNA Verona Pharma Ltd. | 5.21% | 660,000 | $30.7M | Add +1.5% |
| MDGL Madrigal Pharmaceuticals Inc. | 4.33% | 82,500 | $25.5M | Reduce -17.5% |
| CRNX Crinetics Pharmaceuticals Inc. | 4.00% | 460,000 | $23.5M | Add +15.0% |
| NUVL Nuvalent Inc. Class A | 3.79% | 285,000 | $22.3M | Reduce -15.6% |
| SYRE Spyre Therapeutics Inc. | 3.26% | 824,328 | $19.2M | Add +65.4% |
| WVE Wave Life Sciences Ltd. | 3.15% | 1,500,000 | $18.6M | Add +7.1% |
| CNTA Centessa Pharmaceuticals Ltd. | 3.12% | 1,095,924 | $18.4M | Add +13.5% |
| VERA Vera Therapeutics Inc. | 3.06% | 425,000 | $18.0M | Reduce -2.3% |
| NRIX Nurix Therapeutics Inc. | 3.01% | 940,083 | $17.7M | Add +9.3% |
| MRUS Merus NV | 2.78% | 389,241 | $16.4M | Add +140.7% |
| ESTA Establishment Labs Holdings | 2.19% | 279,445 | $12.9M | Reduce -3.8% |
| ARVN Arvinas Inc. | 2.05% | 630,000 | $12.1M | Add +180.0% |
| INZY Inozyme Pharma Inc. | 1.87% | 3,972,318 | $11.0M | Add +40.8% |
| NAMS Newamsterdam Pharma Co. NV | 1.86% | 425,000 | $10.9M | Reduce -10.0% |
| AUTL Autolus Therapeutics PLC | 1.80% | 4,500,000 | $10.6M | No change |
| GERN Geron Corp. | 1.35% | 2,250,000 | $8.0M | Add +50.0% |
| RZLT Rezolute Inc. | 1.31% | 1,575,000 | $7.7M | Reduce -7.3% |
| PRQR Proqr Therapeutics NV | 1.27% | 2,825,000 | $7.5M | New |
| ORKA Oruka Therapeutics Inc. | 1.22% | 368,698 | $7.1M | Add +5.4% |
| AXSM Axsome Therapeutics Inc. | 1.08% | 75,000 | $6.3M | Reduce -6.3% |
| ERAS Erasca Inc. | 1.07% | 2,499,431 | $6.3M | No change |
| SLNO Soleno Therapeutics Inc. | 0.99% | 130,000 | $5.8M | Add +420.0% |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.96% | 300,000 | $5.6M | Reduce -7.7% |
| BBIO Bridgebio Pharma Inc. | 0.93% | 200,000 | $5.5M | Reduce -33.3% |
| PTGX Protagonist Therapeutics Inc. | 0.85% | 130,000 | $5.0M | New |
| MLYS Mineralys Therapeutics Inc. | 0.73% | 350,000 | $4.3M | No change |
| CATX Perspective Therapeutics Inc. | 0.70% | 1,300,000 | $4.1M | Add +160.0% |
| AVTX Avalo Therapeutics Inc. | 0.70% | 550,765 | $4.1M | Add +1123.9% |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.61% | 350,000 | $3.6M | No change |
| TVTX Travere Therapeutics Inc. | 0.59% | 200,000 | $3.5M | New |
| INSM Insmed Inc. | 0.59% | 50,000 | $3.5M | No change |
| CMPS Compass Pathways PLC | 0.55% | 850,512 | $3.2M | Add +183.0% |
| CGEM Cullinan Therapeutics Inc. | 0.55% | 263,817 | $3.2M | No change |
| VRDN Viridian Therapeutics Inc. | 0.52% | 159,614 | $3.1M | Reduce -69.6% |
| MIRM Mirum Pharmaceuticals Inc. | 0.50% | 70,742 | $2.9M | Reduce -5.7% |
| CGON CG Oncology Inc. | 0.49% | 100,000 | $2.9M | New |
| TECX Tectonic Therapeutic Inc. | 0.46% | 58,331 | $2.7M | No change |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.45% | 250,000 | $2.6M | No change |
| OACCU Oaktree Acquisition III Life | 0.43% | 250,000 | $2.5M | New |
| IMVT Immunovant Inc. | 0.42% | 100,000 | $2.5M | Reduce -55.6% |
| AEROVATE THERAPEUTICS INC | 0.36% | 800,000 | $2.1M | Add +33.3% |
| PCVX Vaxcyte Inc. | 0.35% | 25,000 | $2.0M | Reduce -50.0% |
| NKTX Nkarta Inc. | 0.34% | 800,000 | $2.0M | Add +23.1% |
| NXTC Nextcure Inc. | 0.30% | 2,302,598 | $1.8M | No change |
| AVR Anteris Technologies Global | 0.28% | 300,000 | $1.7M | New |
| KYMR Kymera Therapeutics Inc. | 0.27% | 40,000 | $1.6M | New |
| APLS Apellis Pharmaceuticals Inc. | 0.27% | 50,000 | $1.6M | New |
| RAPT THERAPEUTICS INC | 0.27% | 1,000,000 | $1.6M | New |
| NARI Inari Medical Inc. | 0.22% | 25,000 | $1.3M | Reduce -58.3% |
| SVRA Savara Inc. | 0.21% | 410,586 | $1.3M | Reduce -41.3% |
| OKUR Onkure Therapeutics Inc. Class A | 0.21% | 144,159 | $1.2M | New |
| BDTX Black Diamond Therapeutics I | 0.20% | 559,163 | $1.2M | New |
| CNTX Context Therapeutics Inc. | 0.18% | 1,015,340 | $1.1M | Reduce -23.1% |
| KZR Kezar Life Sciences Inc. | 0.16% | 142,316 | $956K | Reduce -43.3% |
| CLYM Climb Bio Inc. | 0.15% | 500,000 | $900K | Reduce -66.7% |
| RADX Radiopharm Theranostics Ltd. | 0.12% | 156,171 | $684K | New |
| ZURA Zura Bio Ltd. | 0.09% | 223,335 | $558K | No change |
| CLDX Celldex Therapeutics Inc. | 0.04% | 9,992 | $252K | Reduce -92.0% |
| ADGM Adagio Medical Holdings Inc. | 0.04% | 213,235 | $224K | No change |
| RPTX Repare Therapeutics Inc. | 0.02% | 100,000 | $131K | Reduce -42.3% |
| OMER Omeros Corp. | 0.02% | 9,958 | $98K | New |
| QTTB Q32 Bio Inc. | 0.02% | 27,777 | $96K | No change |
| SYRS Syros Pharmaceuticals Inc. | 0.01% | 150,000 | $34K | New |
Options reported separately and not counted above: XBI puts ($67.5M), MESO puts ($16.6M), AMGN calls ($7.8M), NMRA calls ($5.0M), FLNA puts ($4.1M), GALT puts ($3.2M), IBRX puts ($640K), BMEA puts ($582K), SYRS puts ($354K), SLNO calls ($9K).
Other holdings (7): bonds, preferreds, convertibles and warrants · $51.8M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| COHERUS ONCOLOGY INC (CHRS 1.5 04/15/26) | NOTE 1.500% 4/1 · principal | 16,625,000 | $16.2M | No change |
| OMEROS CORP (OMER 5.25 02/15/26) | NOTE 5.250% 2/1 · principal | 15,525,000 | $14.6M | Reduce -27.9% |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | NOTE 3.000%10/1 · principal | 15,250,000 | $11.9M | Add +24.5% |
| TRAVERE THERAPEUTICS INC (TVTX 2.25 03/01/29) | NOTE 2.250% 3/0 · principal | 6,000,000 | $5.7M | Add +20.0% |
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | 237,935 | $3.3M | Add +11.7% |
| IMTXW Immatics NV -CW | *W EXP 07/01/202 | 187,204 | $47K | No change |
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 75,000 | $3K | No change |
Total filed on the 13F, all lines: $640.1M.
Portfolio Sells Q3 2024 → Q4 2024
| KURA Kura Oncology Inc. | Sold out | 0.00% | −2.24 |
| NUVL Nuvalent Inc. Class A | Reduce -15.6% | 3.79% | −1.95 |
| VRDN Viridian Therapeutics Inc. | Reduce -69.6% | 0.52% | −1.47 |
| ATXS Astria Therapeutics Inc. | Sold out | 0.00% | −1.33 |
| ONC Beone Medicines Ltd.-ADR | Sold out | 0.00% | −1.31 |
| CLYM Climb Bio Inc. | Reduce -66.7% | 0.15% | −1.12 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −0.83 |
| SWTX Springworks Therapeutics Inc. | Sold out | 0.00% | −0.79 |
| CLDX Celldex Therapeutics Inc. | Reduce -92.0% | 0.04% | −0.66 |
| IMVT Immunovant Inc. | Reduce -55.6% | 0.42% | −0.65 |
| PCVX Vaxcyte Inc. | Reduce -50.0% | 0.35% | −0.60 |
| IMTX Immatics NV | Sold out | 0.00% | −0.47 |
| ROIV Roivant Sciences Ltd. | Sold out | 0.00% | −0.39 |
| BBIO Bridgebio Pharma Inc. | Reduce -33.3% | 0.93% | −0.34 |
| SVRA Savara Inc. | Reduce -41.3% | 0.21% | −0.28 |
| CNTX Context Therapeutics Inc. | Reduce -23.1% | 0.18% | −0.25 |
| VSTM Verastem Inc. | Sold out | 0.00% | −0.20 |
| NARI Inari Medical Inc. | Reduce -58.3% | 0.22% | −0.19 |
| BMRN Biomarin Pharmaceutical Inc. | Sold out | 0.00% | −0.18 |
| KZR Kezar Life Sciences Inc. | Reduce -43.3% | 0.16% | −0.16 |
| VERA Vera Therapeutics Inc. | Reduce -2.3% | 3.06% | −0.14 |
| AXSM Axsome Therapeutics Inc. | Reduce -6.3% | 1.08% | −0.12 |
| PBYI Puma Biotechnology Inc. | Sold out | 0.00% | −0.11 |
| KYTX Kyverna Therapeutics Inc. | Sold out | 0.00% | −0.10 |
| ARWR Arrowhead Pharmaceuticals Inc. | Reduce -7.7% | 0.96% | −0.09 |
| RPTX Repare Therapeutics Inc. | Reduce -42.3% | 0.02% | −0.08 |
| RZLT Rezolute Inc. | Reduce -7.3% | 1.31% | −0.06 |
| VYGR Voyager Therapeutics Inc. | Sold out | 0.00% | −0.05 |
| MTVA Metavia Inc. | Sold out | 0.00% | −0.05 |
| GNLX Genelux Corp. | Sold out | 0.00% | −0.04 |
| WHWK Whitehawk Therapeutics Inc. | Sold out | 0.00% | −0.02 |
| PMN Promis Neurosciences Inc. | Sold out | 0.00% | −0.01 |
| MIRM Mirum Pharmaceuticals Inc. | Reduce -5.7% | 0.50% | +0.01 |
| ESTA Establishment Labs Holdings | Reduce -3.8% | 2.19% | +0.10 |
| NAMS Newamsterdam Pharma Co. NV | Reduce -10.0% | 1.86% | +0.55 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -17.5% | 4.33% | +0.80 |
Portfolio Buys Q3 2024 → Q4 2024
| VRNA Verona Pharma Ltd. | Add +1.5% | 5.21% | +2.10 |
| MRUS Merus NV | Add +140.7% | 2.78% | +1.44 |
| PRQR Proqr Therapeutics NV | New | 1.27% | +1.27 |
| WVE Wave Life Sciences Ltd. | Add +7.1% | 3.15% | +1.24 |
| ARVN Arvinas Inc. | Add +180.0% | 2.05% | +1.13 |
| PTGX Protagonist Therapeutics Inc. | New | 0.85% | +0.85 |
| SYRE Spyre Therapeutics Inc. | Add +65.4% | 3.26% | +0.82 |
| SLNO Soleno Therapeutics Inc. | Add +420.0% | 0.99% | +0.78 |
| ALKS Alkermes PLC | Add +10.0% | 5.38% | +0.72 |
| APGE Apogee Therapeutics Inc. | Add +40.3% | 7.17% | +0.68 |
| AVTX Avalo Therapeutics Inc. | Add +1123.9% | 0.70% | +0.62 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +15.0% | 4.00% | +0.60 |
| TVTX Travere Therapeutics Inc. | New | 0.59% | +0.59 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +13.5% | 3.12% | +0.55 |
| CGON CG Oncology Inc. | New | 0.49% | +0.49 |
| OACCU Oaktree Acquisition III Life | New | 0.43% | +0.43 |
| AVR Anteris Technologies Global | New | 0.28% | +0.28 |
| KYMR Kymera Therapeutics Inc. | New | 0.27% | +0.27 |
| APLS Apellis Pharmaceuticals Inc. | New | 0.27% | +0.27 |
| RAPT THERAPEUTICS INC | New | 0.27% | +0.27 |
| XENE Xenon Pharmaceuticals Inc. | Add +1.5% | 7.74% | +0.24 |
| CMPS Compass Pathways PLC | Add +183.0% | 0.55% | +0.23 |
| GERN Geron Corp. | Add +50.0% | 1.35% | +0.22 |
| OKUR Onkure Therapeutics Inc. Class A | New | 0.21% | +0.21 |
| BDTX Black Diamond Therapeutics I | New | 0.20% | +0.20 |
| AEROVATE THERAPEUTICS INC | Add +33.3% | 0.36% | +0.15 |
| RADX Radiopharm Theranostics Ltd. | New | 0.12% | +0.12 |
| OMER Omeros Corp. | New | 0.02% | +0.02 |
| SYRS Syros Pharmaceuticals Inc. | New | 0.01% | +0.01 |
| ACLX Arcellx Inc. | Add +6.3% | 5.54% | −0.02 |
| NKTX Nkarta Inc. | Add +23.1% | 0.34% | −0.15 |
| NRIX Nurix Therapeutics Inc. | Add +9.3% | 3.01% | −0.21 |
| ORKA Oruka Therapeutics Inc. | Add +5.4% | 1.22% | −0.21 |
| CATX Perspective Therapeutics Inc. | Add +160.0% | 0.70% | −0.41 |
| INZY Inozyme Pharma Inc. | Add +40.8% | 1.87% | −0.59 |
Options Activity Q3 2024 → Q4 2024
| XBI SS SPDR S&P Biotech ETF | put | New | 750,000 | $67.5M |
| TEVA Teva Pharmaceutical-SP ADR | call | Sold out | 1,000,000 | $18.0Mbefore exit |
| MESO Mesoblast Ltd.- Spon ADR | put | New | 838,600 | $16.6M |
| AMGN Amgen Inc. | call | New | 30,000 | $7.8M |
| ANAB Anaptysbio Inc. | put | Sold out | 200,000 | $6.7Mbefore exit |
| SPRY Ars Pharmaceuticals Inc. | call | Sold out | 400,000 | $5.8Mbefore exit |
| NMRA Neumora Therapeutics Inc. | call | New | 475,000 | $5.0M |
| FLNA Filana Therapeutics Inc. | put | Add +20.0% | 1,739,400 | $4.1M |
| NVAX Novavax Inc. | call | Sold out | 300,000 | $3.8Mbefore exit |
| GALT Galectin Therapeutics Inc. | put | Add +105.7% | 2,492,000 | $3.2M |
| SMMT Summit Therapeutics Inc. | call | Sold out | 140,000 | $3.1Mbefore exit |
| IMVT Immunovant Inc. | call | Sold out | 78,000 | $2.2Mbefore exit |
| IBRX Immunitybio Inc. | put | New | 250,000 | $640K |
| BMEA Biomea Fusion Inc. | put | New | 150,000 | $582K |
| SYRS Syros Pharmaceuticals Inc. | put | Add +24.9% | 1,541,200 | $354K |
| SLNO Soleno Therapeutics Inc. | call | New | 200 | $9K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q3 2024 → Q4 2024
| OMEROS CORP (OMER 5.25 02/15/26) | NOTE 5.250% 2/1 · principal | Reduce -27.9% | 15,525,000 | $14.6M |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | NOTE 3.000%10/1 · principal | Add +24.5% | 15,250,000 | $11.9M |
| TRAVERE THERAPEUTICS INC (TVTX 2.25 03/01/29) | NOTE 2.250% 3/0 · principal | Add +20.0% | 6,000,000 | $5.7M |
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | Add +11.7% | 237,935 | $3.3M |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 99 | $2.0B | ROIV, APGE, SYRE, XENE, ERAS |
| Q1 2026 | 90 | $1.7B | APGE, XENE, ERAS, INSM, ROIV |
| Q4 2025 | 80 | $1.3B | APGE, INSM, ABVX, VTYX, XENE |
| Q3 2025 | 80 | $1.0B | VRNA, INSM, SPY, XENE, MDGL |
| Q2 2025 | 71 | $648.9M | VRNA, INSM, XENE, ACLX, BPMC |
| Q1 2025 | 75 | $603.1M | XENE, APGE, VRNA, ACLX, ALKS |
| Q4 2024 | 68 | $588.3M | XENE, APGE, ACLX, ALKS, TEVA |
| Q3 2024 | 70 | $601.0M | XENE, APGE, NUVL, ACLX, ALKS |
| Q2 2024 | 78 | $576.0M | XENE, APGE, MDGL, ACLX, TEVA |
| Q1 2024 | 69 | $571.1M | APGE, XENE, MDGL, CRNX, AUTL |